Andrew Baum
Stock Analyst at Citigroup
(2.86)
# 1,773
Out of 4,975 analysts
65
Total ratings
72.09%
Success rate
13.26%
Average return
Main Sectors:
Stocks Rated by Andrew Baum
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintains: Neutral | $25 → $26 | $24.88 | +4.50% | 11 | Aug 6, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $51 → $47 | $47.14 | -0.30% | 12 | Aug 1, 2025 | |
| MRK Merck & Co. | Downgrades: Neutral | $115 → $84 | $84.71 | -0.84% | 14 | May 14, 2025 | |
| RPRX Royalty Pharma | Maintains: Buy | $60 → $40 | $36.07 | +10.90% | 2 | Oct 25, 2024 | |
| ABBV AbbVie | Maintains: Buy | $170 → $215 | $212.56 | +1.15% | 10 | Oct 25, 2024 | |
| LLY Eli Lilly and Company | Maintains: Buy | $675 → $895 | $727.21 | +23.07% | 11 | Apr 2, 2024 | |
| ALVO Alvotech | Upgrades: Neutral | $5 → $10 | $8.33 | +20.12% | 3 | Oct 20, 2023 | |
| GSK GSK plc | Downgrades: Neutral | n/a | $40.50 | - | 2 | Jul 5, 2017 |
Pfizer
Aug 6, 2025
Maintains: Neutral
Price Target: $25 → $26
Current: $24.88
Upside: +4.50%
Bristol-Myers Squibb Company
Aug 1, 2025
Maintains: Neutral
Price Target: $51 → $47
Current: $47.14
Upside: -0.30%
Merck & Co.
May 14, 2025
Downgrades: Neutral
Price Target: $115 → $84
Current: $84.71
Upside: -0.84%
Royalty Pharma
Oct 25, 2024
Maintains: Buy
Price Target: $60 → $40
Current: $36.07
Upside: +10.90%
AbbVie
Oct 25, 2024
Maintains: Buy
Price Target: $170 → $215
Current: $212.56
Upside: +1.15%
Eli Lilly and Company
Apr 2, 2024
Maintains: Buy
Price Target: $675 → $895
Current: $727.21
Upside: +23.07%
Alvotech
Oct 20, 2023
Upgrades: Neutral
Price Target: $5 → $10
Current: $8.33
Upside: +20.12%
GSK plc
Jul 5, 2017
Downgrades: Neutral
Price Target: n/a
Current: $40.50
Upside: -